Description

Buy Lynparza (Olaparib) For Sale Online USA

Olaparib (Lynparza) is a PARP inhibitor used to treat types of breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, fallopian tube cancer, or peritoneal cancer. Olaparib works by blocking a protein called PARP which helps cancer cells repair themselves, blocking PARP causes the cancer cells die.

Olaparib is often used if your cancer has a specific genetic marker, including BRAC1, BRCA2, HRR, and HER2-negative. Your doctor will test you for this gene.

Olaparib is a tablet that is usually taken twice daily, with or without food.

Lynparza was first FDA-approved in 2014 for advanced ovarian cancer.

What is Olaparib used for?

Olaparib is FDA-approved to treat specific types of cancer.

BRCA-mutated Advanced Ovarian cancer

• first-line maintenance treatment,
• adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer,
• who are in complete or partial response to first-line platinum-based chemotherapy.
• patients should be selected based on an FDA-approved companion diagnostic for this medicine.

 HRD-positive Advanced Ovarian Cancer

• first-line maintenance treatment in combination with bevacizumab
• adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are an incomplete or partial response to first-line platinum-based chemotherapy
• Cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability
• patients should be selected based on an FDA-approved companion diagnostic for this medicine.

Recurrent Ovarian Cancer

• maintenance treatment
• adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy.

Germline BRCA-mutated HER2-negative High-Risk Early Breast Cancer

• adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy
• patients should be selected based on an FDA-approved companion diagnostic for this medicine.

Germline BRCA-mutated HER2-negative Metastatic Breast Cancer

• adult patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting  Buy Lynparza (Olaparib) For Sale Online USA
• Patients with hormone receptor (HR)-positive breast cancer should have been treated with prior endocrine therapy or be considered inappropriate for endocrine therapy
• patients should be selected based on an FDA-approved companion diagnostic for this medicine.